Global Conference 2011

Global Conference 2011

Purpose and Partners: Yielding Return on Medical Research Investments

Monday, May 2, 2011 / 2:30 pm - 3:40 pm

There is a growing "Valley of Death" in funding for the development of new disease treatments. Investment is needed to turn promising discoveries into products. But fiscal realities are causing government, researchers, industry and venture capital funders of medical research to become increasingly conservative and risk-averse in their approaches to R&D and deal-making, despite the fact that the threat to pharmaceutical companies' pipelines has never been greater. The need for new financing models and return on medical research investment is acute. This panel will highlight some alternative and novel mechanisms for identifying and funding high-impact research that can deliver medical solutions to patients.


Margaret Anderson

Executive Director, FasterCures / The Center for Accelerating Medical Solutions


Ali Andalibi

Head, Therapeutics and Diagnostics Section, SBIR Development Center, National Cancer Institute

Catherine Arnold

Managing Director and Global Head of Biopharmaceutical Equity Research, Credit Suisse

Christopher Elias

President and CEO, PATH

Stephen Seiler


Daniel Wattendorf

Lt. Colonel, USAF MC; Program Manager, Defense Advanced Research Projects Agency (DARPA), Defense Sciences Office

Return to Program Detail